Clinical Evidence

Summary/Conclusion

IOERT resulted in a reduction of treatment time, was not associated with additional toxicity or change in the acute toxicity profile, and is a feasible treatment option in a community setting.

Summary/Conclusion

IOERT is a feasible technique and can be viewed as a tool in the treatment of newly diagnosed and recurrent brain gliomas.

Summary/Conclusion

Both univariate and multivariate analysis revealed the survival rate was significantly higher in patients that received IORT than in those that did not (p = 0.026). There were no perioperative complications attributed to IORT. IORT for esophageal carcinoma will likely be effective for patients with a primary lesion in the lower thoracic or abdominal esophagus, or with a long lesion.

Summary/Conclusion

APBI using a single dose of IOERT can be delivered safely in women with early, low-risk breast cancer in carefully selected patients.

Summary/Conclusion

In patients with recurrent or advanced urothelial carcinoma, this multimodality approach yielded a low rate of recurrence with an acceptable toxicity.